Is there a cancer concern with calcitonin?

Yes. Meta-analyses linked long-term use, especially the nasal spray, to a small increased overall cancer risk, which led the EMA to restrict long-term osteoporosis use and recommend the shortest effective course.

How does calcitonin protect bone?

It binds calcitonin receptors on osteoclasts to slow bone breakdown, which lowers serum calcium and can reduce bone loss and pain.

Is calcitonin a first-line osteoporosis treatment?

No longer. Because of the benefit-risk reassessment and only modest fracture protection, it is generally reserved for specific indications and limited durations rather than long-term first-line use.

It has been used as an injection for hypercalcemia and Paget disease and as a nasal spray for osteoporosis, always for the shortest clinically justified period under medical supervision.

EMA-approvedaka Miacalcin, Fortical, Calcitonin-salmon

Salmon calcitonin — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Salmon calcitonin (also known as Miacalcin) is a peptide catalogued under Hormones & Metabolic (Calcitonin analog). It is described as: Calcitonin receptor agonist. Documented context: Osteoporosis; Paget disease; hypercalcemia. Neutral reference entry; EU status: EU-approved prescription medicine.

What is Salmon calcitonin?

Salmon calcitonin is a peptide hormone analog approved for hypercalcemia, Paget disease of bone, and postmenopausal osteoporosis, available as an injection and, historically, as a nasal spray.

Regulators have restricted long-term use: meta-analyses linked prolonged calcitonin (especially intranasal) to a small increased overall cancer risk, and the EMA restricted its long-term osteoporosis use, recommending the shortest effective duration.

Human evidence includes a large randomized fracture trial (PROOF), though its overall osteoporosis benefit is considered modest.

How does Salmon calcitonin work?

Salmon calcitonin binds calcitonin receptors on osteoclasts, inhibiting bone resorption and lowering serum calcium; it also has a documented analgesic effect on bone pain.

The salmon form is more potent and longer-acting at the human receptor than native human calcitonin.

What does the research say about Salmon calcitonin?

In the randomized PROOF trial, nasal salmon calcitonin 200 IU/day reduced new vertebral fracture risk in postmenopausal women with osteoporosis, though effects at other doses and sites were inconsistent. ^[1]
A systematic review and meta-analysis found calcitonin significantly reduces pain from acute and chronic osteoporotic vertebral compression fractures. ^[2]
Calcitonin remains an established option across its approved indications, including Paget disease of bone, hypercalcemia, and osteoporosis-related bone pain. ^[5]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group — Chesnut CH 3rd et al., The American Journal of Medicine 2000. (Randomized controlled trial)
[2] Calcitonin for treating acute and chronic pain of recent and remote osteoporotic vertebral compression fractures: a systematic review and meta-analysis — Knopp-Sihota JA et al., Osteoporosis International 2012. (Systematic review and meta-analysis)
[3] Salmon calcitonin use and associated cancer risk — Overman RA et al., Annals of Pharmacotherapy 2013. (Systematic review of trial safety data)
[4] Salmon calcitonin: a review of current and future therapeutic indications — Chesnut CH 3rd et al., Osteoporosis International 2008. (Narrative review)
[5] Calcitonin for osteoporosis and bone pain — Mehta NM et al., Current Pharmaceutical Design 2003. (Narrative review)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

Depending on indication it has been used as a subcutaneous or intramuscular injection (for hypercalcemia and Paget disease) or as a once-daily nasal spray (for osteoporosis), for as short a period as clinically justified.

This is context only and not a dosing recommendation; product availability, indication, and duration must follow current labeling and a clinician's judgment.

Side effects & safety profile

Cancer-signal caution: pooled analyses associated long-term calcitonin use with a small increase in overall malignancy, prompting the EMA to restrict long-term (particularly intranasal) use for osteoporosis and to advise the shortest possible treatment duration.

Common side effects include nasal irritation and rhinitis with the spray, and nausea, flushing, or injection-site reactions with the injectable form.

Because of the benefit-risk reassessment, calcitonin is generally not a first-line long-term osteoporosis therapy and is used for defined indications and limited durations under medical supervision.

Stacking & combinations

Calcitonin is a regulated bone medicine used within specific indications and is not appropriate for combining with other peptides for non-medical or performance purposes.

Finding Salmon calcitonin vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

It is approved for hypercalcemia, Paget disease of bone, and postmenopausal osteoporosis, and it is also used to relieve certain osteoporotic bone pain.

References

[1] A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group — Chesnut CH 3rd et al., The American Journal of Medicine 2000. PMID: 10996576. View sourceStudy: Randomized controlled trialNasal salmon calcitonin 200 IU/day reduced new vertebral fracture risk, though results across doses and non-vertebral sites were inconsistent.
[2] Calcitonin for treating acute and chronic pain of recent and remote osteoporotic vertebral compression fractures: a systematic review and meta-analysis — Knopp-Sihota JA et al., Osteoporosis International 2012. PMID: 21660557. View sourceStudy: Systematic review and meta-analysisCalcitonin significantly reduced pain from acute and chronic osteoporotic vertebral compression fractures.
[3] Salmon calcitonin use and associated cancer risk — Overman RA et al., Annals of Pharmacotherapy 2013. PMID: 24259626. View sourceStudy: Systematic review of trial safety dataReviewed the meta-analytic signal of a small increased overall malignancy risk with salmon calcitonin that drove regulatory restrictions.
[4] Salmon calcitonin: a review of current and future therapeutic indications — Chesnut CH 3rd et al., Osteoporosis International 2008. PMID: 18071651. View sourceStudy: Narrative reviewReviews salmon calcitonin's approved indications, antiresorptive and analgesic actions, and clinical role.
[5] Calcitonin for osteoporosis and bone pain — Mehta NM et al., Current Pharmaceutical Design 2003. PMID: 14529539. View sourceStudy: Narrative reviewReviews calcitonin's use in osteoporosis and its analgesic effect on bone pain across indications.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.